SCHEMBL2600568

SCHEMBL2600568

COc1ccccc1-c1c[nH]c2ncc(-c3cccc(C(=O)N(C)C)c3)c(C#N)c12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 2/20 0.57
MAP4K1 Q92918 2/20 0.49
IGF1R P08069 7/20 0.47
JAK2 O60674 1/20 0.45
JAK3 P52333 1/20 0.45
LRRK2 Q5S007 1/20 0.45
CYP3A4 P08684 1/20 0.44
AXL P30530 2/20 0.43
DYRK3 O43781 1/20 0.42
ROCK2 O75116 1/20 0.42
PRKD3 O94806 1/20 0.42
MAP4K4 O95819 1/20 0.42
NTRK1 P04629 1/20 0.42
LCK P06239 1/20 0.42
CDK1 P06493 1/20 0.42
FGFR1 P11362 1/20 0.42
RPS6KB1 P23443 1/20 0.42
MARK3 P27448 1/20 0.42
FLT4 P35916 1/20 0.42
FLT3 P36888 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2600570 0.91 ABL1 (0.67) ABL1MAP4K1IGF1RJAK2JAK3
SCHEMBL2600548 0.90 ABL1 (0.48) ABL1MAP4K1IGF1RLRRK2CYP3A4
SCHEMBL2600528 0.87 ABL1 (0.60) ABL1MAP4K1IGF1RJAK2JAK3
SCHEMBL2112267 0.87 ABL1 (0.60) ABL1MAP4K1IGF1RJAK2JAK3
SCHEMBL2112147 0.86 ABL1 (0.59) ABL1MAP4K1IGF1RJAK2JAK3
SCHEMBL2600541 0.86 ABL1 (0.59) ABL1MAP4K1IGF1RJAK2JAK3
SCHEMBL2600576 0.85 MAP4K1 (0.58) ABL1MAP4K1JAK2JAK3LRRK2
SCHEMBL2600524 0.84 ABL1 (0.58) ABL1MAP4K1IGF1RJAK2JAK3
SCHEMBL2600527 0.84 ABL1 (0.57) ABL1MAP4K1IGF1RJAK2JAK3
SCHEMBL2600554 0.81 ABL1 (0.54) ABL1MAP4K1LRRK2CYP3A4ROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8158647-B2 Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators SGX PHARMACEUTICALS, INC. (US) 2012-04-17 US disclosed
US-20090005356-A1 SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS SGX PHARMACEUTICALS, INC. (US) 2009-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090005356-A1 SUBSTITUTED PYRROLOPYRIDINES AND PYRAZOLOPYRIDINES AS KINASE MODULATORS PDXK, MAP3K4, PDPK1 ABL1 862/4885MAP4K1 16/4885IGF1R 1011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.